The Alliance is an experienced multi-institutional cancer clinical trials group that has been reorganized in response to the Institute of Medicine (lOM) consensus report and NCI directives for cooperative group reorganization. Alliance provides a comprehensive and highly efficient clinical trials infrastructure, access to experienced collaborators across all disciplines of oncology clinical trials research, and a diverse portfolio f trials for patients with breast, gastrointestinal, genitourinary, respiratory, central nervous systm, hematological malignancies, and selected rare tumors. Particular strengths of the Alliance include the long-standing tradition of collaborative research of the legacy members, including many who have participated in cooperative group research since its inception in 1955. The Mission of the Alliance for Clinical Trials in Oncology is to reduce the impact of cancer by: - Conducting high quality multidisciplinary cancer control, prevention, and treatment trials that engage a comprehensive research network; - Furthering our understanding of the biological basis of the cancer process and its treatment; from discovery, to validation, to clinical practice;- Providing a scientific and operational infrastructure for innovative clinical and translational research in the academic and community settings.

Public Health Relevance

To reduce the impact of cancer on people by uniting a broad community of scientists and clinicians from many disciplines, committed to discovering, validating and disseminating effective strategies for the prevention and treatment of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA180821-03S2
Application #
9337542
Study Section
Special Emphasis Panel (ZCA1-GRB-I (O1))
Program Officer
Mooney, Margaret M
Project Start
2014-04-17
Project End
2019-02-28
Budget Start
2016-03-01
Budget End
2017-02-28
Support Year
3
Fiscal Year
2016
Total Cost
$550,000
Indirect Cost
$6,750
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Van Blarigan, Erin L; Ou, Fang-Shu; Niedzwiecki, Donna et al. (2018) Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:1227-1230
Fleshman, James; Branda, Megan E; Sargent, Daniel J et al. (2018) Disease-free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer: Follow-up Results of the ACOSOG Z6051 Randomized Controlled Trial. Ann Surg :
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Miller, Kathy D; O'Neill, Anne; Gradishar, William et al. (2018) Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol 36:2621-2629
Hager, Rebecca; Tsiatis, Anastasios A; Davidian, Marie (2018) Optimal two-stage dynamic treatment regimes from a classification perspective with censored survival data. Biometrics :
Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia 32:1338-1348
Li, Daneng; McCall, Linda M; Hahn, Olwen M et al. (2018) Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Breast Cancer Res Treat 171:325-334
Rimsza, Lisa M; Li, Hongli; Braziel, Rita M et al. (2018) Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. Haematologica 103:e151-e153
Kyriakopoulos, Christos E; Chen, Yu-Hui; Carducci, Michael A et al. (2018) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol 36:1080-1087

Showing the most recent 10 out of 325 publications